alfuzosin (SL770499)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder Neurogenic
Conditions
Urinary Bladder Neurogenic
Trial Timeline
Jul 1, 2006 → Feb 1, 2007
NCT ID
NCT00629720About alfuzosin (SL770499)
alfuzosin (SL770499) is a phase 3 stage product being developed by Sanofi for Urinary Bladder Neurogenic. The current trial status is completed. This product is registered under clinical trial identifier NCT00629720. Target conditions include Urinary Bladder Neurogenic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00629720 | Phase 3 | Completed |
| NCT00029822 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Bladder Neurogenic